Article Details

ExeVir receives EIB risk finance for multiple COVID-19 nanobody - European Biotechnology

Retrieved on: 2023-01-09 11:17:59

Tags for this article:

Click the tags to see associated articles and topics

ExeVir receives EIB risk finance for multiple COVID-19 nanobody - European Biotechnology. View article details on HISWAI: https://european-biotechnology.com/up-to-date/latest-news/news/exevir-receives-eib-risk-finance-for-multiple-covid-19-nanobody.html

Excerpt

With the help of a €25m loan from the European Investment Bank, ExeVir BIO BV will advance clinical trials with its COVID-19 nanobody XVR012.

Article found on: european-biotechnology.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up